Did No­var­tis get $150M worth of pos­i­tive PhII car­dio da­ta from Akcea?

Akcea has $150 mil­lion rid­ing on the Phase II da­ta it just post­ed for a car­dio drug.

The com­pa­ny $AK­CA, a close­ly held af­fil­i­ate of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.